Objective To report on the cost-effectiveness of the Exercise for Health trial, comparing an exercise intervention with usual care during and following treatment for women with breast cancer.
| BACKGROUND
Long-term sequelae of breast cancer treatment are common; 60% to 70% of breast cancer survivors live with chronic adverse treatmentrelated side effects, such as upper-body symptoms, lymphedema, and/or fatigue. 1 Younger women can experience premature menopause, bone density loss, infertility, and associated distress. 2 With increasing numbers of women diagnosed with breast cancer each year, together with improving survival rates, the need to understand treatment-related concerns and to identify safe, effective, evidencebased strategies to alleviate these side effects and improve quality of life is important.
International cancer organizations recommend cancer survivors to engage in regular physical activity, eat a healthy diet, and aim to keep their weight within a healthy range. 3, 4 Regular, moderate-intensity exercise confers numerous quality of life benefits to women during
| Sample and intervention description
The EfH intervention was a prospective, 3- 
| Data collection
Data were collected at baseline (6 weeks post-surgery), mid-intervention (6 months post-surgery), and post-intervention (12 months postsurgery). At baseline, data items included standard sociodemographics, cancer disease and treatments, and a range of physical tests performed by centrally trained-to-study-protocol exercise physiologists blinded to group allocation. For the current analysis, the main outcomes were number of women with improved quality of life, quality-adjusted life years (QALYs), and intervention costs.
Previously, the EfH intervention has demonstrated significant patient benefits for quality of life, fitness, and fatigue. 23 For the present analysis, the number of women who reported substantial improvements in quality of life was used as a clear indicator of benefit. The FACT-B+4 questionnaire is a multidimensional tool, designed to assess quality of life for women with breast cancer. Quality of life "improvers" were those who reported a clinically important increase of ≥8 points 25 on the FACT-B+4 score (score range, 0-160) between baseline and 12 months post-surgery. As a secondary outcome, because of being generic and widely used in economic evaluations, QALYs were also considered. Quality-adjusted life years are a generic outcome, which combine life years (or survival) and quality of life or health utility. We used the Australian algorithm 26 to obtain a EuroQol-5D (EQ-5D-3L) weight (range, 0-1) and derived QALYs for each participant. In women with breast cancer, convergent validity, internal consistency, and test-retest reliability for the EQ-5D-3L is r > 0.49, α = 0.71, and κ = 0.7, respectively.
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The types of costs included in the analysis were taken from a broad perspective covering health providers, patients, and government. Two cost scenarios were considered: (1) 28 The private model also included patient out-ofpocket expenses but excluded patient travel costs (because of the home-delivered intervention). In both scenarios, costs relating to the routine health care for breast cancer were omitted because these were not expected to differ across the intervention and control arms. No exercise injuries occurred in the trial. Although the face-to-face and telephone intervention modes were separated in the main trial, here, they were pooled because intervention resources were virtually identical, with the exception of vehicle leasing in the service provider model. Vehicle leasing was estimated at current commercial rates, which included financing, fuel, and all servicing for a small car. Costs for the usual care group were minimal and included patient out-ofpocket expenses collected in the trial.
| Data analyses
An intention-to-treat approach was taken to assess differences in the outcomes across the trial arms. All baseline sociodemographic and medical characteristics were compared across the intervention and control arms using χ 2 tests for categorical data and Student t tests for continuous data. Comparing across treatment arms, the minimal important difference for the EQ-5D-3L is in the range of 0.06 to 0.09 points. 27 Generalized estimating equations models were used to assess both time and treatment main, and interaction effects.
Quality-adjusted life years were calculated using all assessments of EuroQol-5D-3L (EQ-5D-3L) and the area-under-the-curve method to produce a single QALY for each person over 12 months. 29 Intervention costs were tallied for all components of the respective cost scenarios.
An equivalent annual cost was used for exercise equipment. 29 The key outcomes were combined into ratios of incremental cost per improver and incremental cost per QALY. These provide the relative cost and health benefits of the intervention versus usual care. Costs were presented in 2014 Australian dollars.
One-way sensitivity analyses were undertaken for the calculated QALYs using the 95% confidence interval for each group and variation in car leasing costs, representing plausible low and high QALYs and cost scenarios. Patient costs for exercise equipment in the intervention group were self-reported but were unknown for the usual care group.
In the base case, it was assumed that 50% of the intervention group costs would apply to the usual care group, and this was tested at 25%, 75%, and 100% in sensitivity analyses. As most costs in the service provider model were collected and valued with point estimates,
we also assessed group costs at ±30% in a sensitivity analysis. Finally, a probabilistic sensitivity analysis was undertaken to assess the likelihood of the intervention being cost-effective. Here, simulation methods were applied, and variables for cost and QALYs were varied simultaneously. Variations in estimates were made using beta distributions for QALYs (using statistical means and standard deviations) and normal distributions for costs (based on means and estimated standard deviations: SD = mean/6). This analysis was performed in TreeAge Pro 2014. 30 To interpret the results, we used a ratio of A$50 000 per QALY gain as an acceptable threshold for cost-effective health care
in line with reimbursement decisions in Australia. 31 
| RESULTS
The intervention and usual care groups were similar with respect to their sociodemographic and clinical characteristics. Women had an average age of 52 ± 8 years and were overweight (mean body mass index = 26.6 ± 5.2 kg/m 2 ), and 30% and 62% were classified as having stage I and II+ disease, respectively.
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The number of improvers was 69 in the intervention group (57%) versus 21 in the usual care group (39%); an intervention effect of 48 additional women exceeding clinically meaningful changes in their health-related quality of life (odds ratio 2.09, 95% confidence interval 1.08, 4.01, P = .033). Table 1 presents the utility scores at baseline, and at 6 and 12 months post-surgery, as well as changes in scores over time. The interaction effect between time and group was statistically significant (P < .05). Compared with the usual care group, the intervention group reported minimally relevant improvements in EQ-5D-3L
weights from baseline to 12 months post-treatment (P < .05). In contrast, weights for the usual care group remained relatively stable over time (Table 1 ). The mean costs per patient for the intervention through a service provider model were A$967, A$838 for the private model and A$20 for usual care ( Table 2 ). The highest proportion of total costs in the service provider model was labor costs (78%) and vehicle leasing costs (5%).
Compared with usual care, the intervention required an additional A$947 to A$818 (depending on service model) to produce 48 additional women with significant improvements to their quality of life or an incremental cost of A$2282 to A$2644 per improver (Table 3) .
Using the secondary outcome of QALYs, the incremental QALY gain for the intervention group was minor at 0.009 (Table 3) . Compared with that for usual care, the cost per QALY gain was A$90 842 and A$105 231 for the 2 service models (Table 3 ). In the sensitivity analyses, variation in costs changed the cost per improver between A$1756 and A$3777 (Table 4) . If the intervention reduced the number of additional "improvers" by 30% from 48 to 34, the incremental cost would be A$3261 to A$3777 per improver. Sensitivity analyses indicated that the incremental cost-effectiveness ratios using QALYs gained were most sensitive when the EQ-5D-3L weights were varied within the 95% confidence limits. The results ranged from A$16 685 per QALY gain to usual care being superior (ie, less expensive and higher QALYs) ( Table 4) . Other variations in variables tested (eg, leasing costs) produced negligible changes to the incremental cost-effectiveness ratios. The likelihood of the service provider model being cost-effective was 44.4%, and 46.3% for the private model, at a willingness-topay threshold of A$50 000 per QALY gain. 31 
| DISCUSSION
In terms of the numbers of women reporting clinically significant improvements in quality of life, the intervention, using either service model, may be cost-effective at approximately A$2400 per improver (or A$300 per month). Notably, the total and mean intervention costs for either service model were low for an 8-month intervention and up to 16 contact sessions per patient. However, the cost-effectiveness of the intervention, for either service model, was more uncertain using QALYs gained as a secondary outcome. These latter findings showed high volatility to the EQ-5D-3L weights, and the likelihood of being cost-effective was 44% to 46%. In this study, the EQ-5D-3L was not sensitive to capture the intervention effect, and therefore, QALYs were not entirely appropriate for this context. When health-related quality of life data were reviewed further, ceiling effects pre-intervention were observed for 25% of the intervention group and 33% of the usual care group. Also of note is that the EfH sample was likely more active at baseline than at the wider breast cancer population. 22 This is not unique to the EfH trial and has been previously identified as a limitation of the generalizability of findings from the majority of exercise intervention trials involving women with breast cancer. 33 Both factors (that is, high quality of life scores and being physically active at time of study commencement) may mean that the intervention and usual care group health utility weights were more similar than might otherwise be true. This would underestimate health utility weights in our cost-effectiveness findings and result in a higher incremental cost per QALY ratio. In addition, several important intervention benefits found in the intervention group, including improved fatigue and fitness, 23 may not be adequately incorporated within these cost-effectiveness analyses.
For example, while the FACT-B+4 includes an item for fatigue, it is not a validated fatigue tool; fitness benefits observed were objectively measured.
Three studies have reported on the cost-effectiveness of exercise interventions among women diagnosed with breast cancer, [34] [35] [36] and 1 for patients with lung cancer. 37 Similarly to our study, the previous cost-effectiveness studies used both short-term patient outcomes and supplemented these with QALYs. Two of the breast cancer studies were based on randomized controlled trials, but the time horizons ).
b Δ mid-pre scores, change between baseline and 6 months post-surgery utility scores; Δ post-pre scores, change between baseline and 12 months post-surgery utility scores c Clinically meaningful difference between groups compared with that of the usual-care group.
d Clinically meaningful change over time. 
